Four Thought Financial, LLC Sage Therapeutics, Inc. Transaction History
Four Thought Financial, LLC
- $677 Million
- Q3 2022
A detailed history of Four Thought Financial, LLC transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Four Thought Financial, LLC holds 138 shares of SAGE stock, worth $1,197. This represents 0.0% of its overall portfolio holdings.
Number of Shares
138
Previous 138
-0.0%
Holding current value
$1,197
Previous $4,000
25.0%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding SAGE
# of Institutions
25Shares Held
6.2MCall Options Held
37.8KPut Options Held
0-
Black Rock Inc. New York, NY5.22MShares$45.3 Million0.0% of portfolio
-
Pictet Asset Management Sa Geneva 73, V8599KShares$5.2 Million0.03% of portfolio
-
Nuveen Asset Management, LLC Chicago, IL143KShares$1.24 Million0.0% of portfolio
-
Credit Suisse Ag Zurich, V8103KShares$897,5640.0% of portfolio
-
Ea Series Trust Havertown, PA57.2KShares$496,0880.09% of portfolio
About Sage Therapeutics, Inc.
- Ticker SAGE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,422,300
- Market Cap $516M
- Description
- Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...